Top Page
Osteopore Ltd.
(Sydney:OSX)
Osteopore Ltd. (OSX) vs. iShares MSCI Australia ETF (EWA)
Osteopore Ltd. Business Overview & Revenue Model
Osteopore Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.89M | 2.81M | 2.22M | 1.69M | 1.11M | 1.50M |
| Gross Profit | 2.30M | 2.37M | 1.64M | 1.27M | 811.64K | 955.33K |
| EBITDA | -2.42M | -2.34M | -4.35M | -3.97M | -3.38M | -1.76M |
| Net Income | -3.26M | -3.35M | -4.87M | -4.22M | -3.62M | -1.95M |
Balance Sheet | ||||||
| Total Assets | 4.19M | 3.13M | 3.34M | 3.62M | 6.01M | 10.25M |
| Cash, Cash Equivalents and Short-Term Investments | 1.81M | 638.50K | 1.16M | 1.35M | 4.55M | 9.03M |
| Total Debt | 1.68M | 1.33M | 1.09M | 74.18K | 106.71K | 453.99K |
| Total Liabilities | 4.62M | 2.83M | 2.91M | 1.51M | 633.40K | 1.25M |
| Stockholders Equity | -423.65K | 306.22K | 432.60K | 2.11M | 5.37M | 9.00M |
Cash Flow | ||||||
| Free Cash Flow | -2.71M | -3.10M | -3.74M | -4.06M | -4.00M | -2.14M |
| Operating Cash Flow | -2.69M | -3.09M | -3.74M | -4.00M | -3.81M | -1.76M |
| Investing Cash Flow | -17.19K | -14.59K | -7.37K | -63.98K | -194.62K | -381.04K |
| Financing Cash Flow | 2.58M | 2.63M | 3.58M | 896.32K | -485.88K | 7.84M |
Osteopore Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | AU$24.32M | -5.23 | -27.84% | ― | 6.77% | -8.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$215.65M | -130.21 | -2.01% | ― | 16.93% | 76.47% | |
49 Neutral | AU$46.78M | -8.29 | -81.30% | ― | -36.68% | 79.41% | |
46 Neutral | AU$5.44M | -0.63 | -487.52% | ― | 5.52% | 49.25% | |
44 Neutral | AU$103.30M | -12.65 | -47.98% | ― | 700.00% | 26.88% | |
41 Neutral | AU$249.60M | -25.63 | -89.70% | ― | 42.05% | -0.84% |
Osteopore Ltd. Corporate Events
Osteopore Ltd has applied to the ASX for quotation of 20 million new fully paid ordinary shares, to be traded under its existing ticker, OSX. The share issuance, dated 27 January 2026, will expand the company’s quoted capital base, potentially improving trading liquidity and providing additional funding capacity, with implications for existing shareholders through capital structure and possible dilution effects.
The most recent analyst rating on (AU:OSX) stock is a Buy with a A$0.02 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has clarified details of its exclusive agreement with MontsMed Hong Kong Company Limited to introduce its custom and off-the-shelf orthopaedic implant products into Hong Kong. While Hong Kong itself is not considered a major bone trauma market, Osteopore emphasises the territory’s strategic role as a regulatory and market gateway into China’s Guangdong-Hong Kong-Macao Greater Bay Area, a region of over 87 million people and RMB 14.5 trillion GDP, positioning the deal as a significant long-term opportunity despite the current inability to quantify its potential economic impact; the agreement is described as containing standard market terms with no additional material conditions or minimum performance criteria.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has signed an exclusive three-year distribution agreement, with an option for a one-year extension, with MontsMed Hong Kong Company Limited to introduce its custom and off-the-shelf orthopaedic products into Hong Kong, initially targeting the orthopaedic trauma reconstruction market where its devices have the strongest application potential. While Hong Kong is a relatively small market, Osteopore’s move positions the company in a strategically important hub to access the Greater Bay Area and benefit from emerging regulatory harmonisation for medical devices across China’s regional healthcare network, aligning the business with a fast-growing Asia-Pacific bone graft and substitutes market projected to expand at an 8.2% CAGR through 2030.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has applied to the ASX for quotation of 10 million new fully paid ordinary shares, with the securities to be issued and quoted on 20 January 2026 under the ticker OSX. The move expands the company’s listed share base and may provide additional capital flexibility and liquidity for existing and new investors, although the announcement does not disclose the purpose of the issuance or associated funding details.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has applied to the Australian Securities Exchange for quotation of 50 million new fully paid ordinary shares, to be traded under its existing ticker, OSX. The securities were issued on 16 January 2026, signaling a significant expansion of the company’s listed share base that may affect its capital structure and liquidity profile, with implications for existing shareholders as the enlarged register comes to market.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has entered an exclusive commercialisation agreement with Majeton to distribute its dental, orthodontic and maxillofacial regenerative implants across China, Hong Kong and Macau, marking a strategic move to penetrate the Greater China market. The deal, effective from 15 January 2026, includes staged payments tied to regulatory and sales milestones, such as upfront dossier fees, payments on regulatory approvals in Macau and China, and volume-based bonuses for units sold in the Greater Bay Area and mainland China, signalling a structured pathway to revenue growth and broader regional adoption of Osteopore’s technology.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has signed a multi-year, exclusive distribution agreement worth more than RMB 12 million with Majeton Pte Ltd to commercialise its dental, orthodontic and maxillofacial products in China, Hong Kong and Macau. The deal, which includes upfront and milestone payments tied to sales and regulatory achievements, gives Osteopore access to the Chinese dental bone graft substitute and membrane market via Majeton and its parent Essex Bio-Technology Limited, whose extensive hospital network and sales infrastructure are expected to accelerate Osteopore’s regional expansion and reinforce its strategy of leveraging established partners to scale commercialisation and improve patient outcomes.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has notified the market of the issue of five unquoted convertible notes under the security code OSXAM, with the issue dated 14 January 2026. The small-scale issuance of these convertible notes indicates the company is continuing to use structured, non-listed securities as part of its capital management strategy, which may provide additional funding flexibility without immediate dilution for ordinary shareholders.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has issued a cleansing notice in connection with a new $250,000 sub‑tranche (ST18 of T1) of redeemable convertible notes subscribed for by Advance Opportunities Fund and Advance Opportunities Fund I under an existing subscription agreement of up to $20 million. The notice confirms that these Sixth Convertible Notes will be issued without a prospectus, and that ordinary shares issued upon their conversion can be freely on‑sold to retail investors, reflecting the company’s continued use of staged convertible note funding to support its capital needs while maintaining compliance with Australian corporate and ASX disclosure requirements.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has drawn a further A$250,000 sub-tranche (ST18) from Tranche 1 of its 4.0% redeemable convertible notes facility with Advance Opportunities Fund and Advance Opportunities Fund I, taking total subscriptions under Tranche 1 to A$4.5 million out of a planned A$5 million. The funds raised under the up-to-A$20 million multi-tranche notes program are earmarked for use in the ordinary course of business and to support future developments, projects and investments as opportunities arise, bolstering Osteopore’s capital position as it seeks to expand its regenerative implant operations and pursue growth initiatives.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Limited has signed an exclusive 15-year licensing agreement with Accelerate Technologies, the commercialisation arm of Singapore’s A*STAR, to use a Heparan Sulphate bioactive technology platform designed to significantly accelerate bone and tissue regeneration when combined with Osteopore’s existing implant technology. The licence, which includes patents and know-how for two Heparan Sulphate families such as HS3 and covers all life science, medical, research and clinical uses across key global markets, positions Osteopore to access the fast-growing bone morphogenetic protein-2 (BMP-2) market in Asia-Pacific, valued at USD 670 million in 2024 and forecast to expand at 8.5% annually, although the company does not expect a short-term material impact on earnings as clinical trials and regulatory milestones progress.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Advance Opportunities Fund I has lodged a notice under Australia’s Corporations Act stating it has ceased to be a substantial shareholder in Osteopore Limited. The filing, dated 30 December 2025, indicates that the fund’s relevant interest in Osteopore’s voting securities has fallen below the substantial holding threshold, signalling a change in the company’s share register that may alter its investor base and potentially affect perceptions of institutional support.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Ltd. has announced the quotation of 16,949,152 new fully paid ordinary securities on the Australian Securities Exchange (ASX) as of December 11, 2025. This move is part of the company’s strategic efforts to enhance its capital structure and potentially expand its market presence, which could have significant implications for its growth and stakeholder value.
The most recent analyst rating on (AU:OSX) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.
Osteopore Ltd. announced the issuance of new unquoted convertible notes, marking a strategic financial move to support its ongoing operations and growth initiatives. This development could enhance the company’s financial flexibility, potentially impacting its market positioning and offering new opportunities for stakeholders.
Osteopore Ltd. has issued a Cleansing Notice related to the issuance of convertible notes under a subscription agreement with Advance Opportunities Fund. This agreement allows the company to raise up to $20 million through redeemable convertible notes, with the latest tranche amounting to $250,000. The issuance of these notes enables the company to convert them into fully paid ordinary shares, which can be sold to retail investors without further disclosure. This financial maneuver is significant for Osteopore as it provides additional capital to support its operations and potentially strengthens its market position in the medical technology sector.
Osteopore Limited has announced a further drawdown of its Tranche 1 redeemable convertible notes, raising an additional A$250,000. This funding, part of a larger A$20 million subscription agreement with Advance Opportunities Fund, will support the company’s ongoing business operations and future development projects. The strategic financial move is expected to bolster Osteopore’s market positioning and facilitate the advancement of its innovative regenerative medicine solutions.
Osteopore Ltd. has announced the quotation of 18,292,682 new ordinary fully paid securities on the Australian Securities Exchange (ASX), effective November 19, 2025. This move is part of the company’s strategic efforts to enhance its market presence and operational capabilities, potentially impacting its financial standing and offering new opportunities for stakeholders.
Osteopore Ltd. has announced that Advance Opportunities Fund I has ceased to be a substantial holder in the company. This change in holdings, involving the indirect sale of shares, may impact the company’s market dynamics and influence stakeholder perceptions regarding the company’s financial stability and investor confidence.
Osteopore Ltd. announced the cessation of 12,500 securities due to the lapse of conditional rights, as the conditions for these securities were not met by the expiration date. This cessation may impact the company’s capital structure and could influence investor perception, reflecting on the company’s ability to meet certain financial or operational conditions.
Osteopore Limited reported a revenue of AUD 812K for the third quarter of 2025, marking a 7% year-over-year growth. The company also achieved a significant milestone by securing market approval in Switzerland under the EU MDR clearance for its custom orthopedic and cranial implants, potentially enhancing its market presence in Europe.